Although CRISPR–Cas first made a splash in gene editing, scientists now use it to precisely target epigenetic editors to any DNA sequence. Nature reports on companies exploring epigenetic-editing technology and a handful of early-stage clinical trials. 🧬🧪
Публикация
Обсуждение
Ответы
Загружаем ответы…